World News

The acquisition grants Biogen access to two already-marketed medications that generated USD689 million in sales last year.

The Raptor™ platform uses advanced genetic engineering tools to produce recombinant biologics inside eggs.

In Japan alone, 21,000 new cases and 7,000 deaths were reported that year, with metastatic renal cell carcinoma (RCC) accounting for approximately 85% of all kidney cancers.

Results confirmed that Caas vFFR is a safe and effective alternative to conventional pressure wire-based physiology for guiding treatment decisions in patients with intermediate coronary artery stenosis.

For MSD, this acquisition is part of a broader strategy to diversify its pipeline before its blockbuster immunotherapy Keytruda loses patent protection.

CVC first invested in Recordati in 2018, paying €3.03 billion (USD 3.5 billion) to acquire a 51.8% controlling stake.

Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.

TB remains the deadliest infectious disease in the world, and a single untreated case can infect between 15 and 20 people within a year, making early diagnosis and uninterrupted treatment critical tools for containing any outbreak.

The acquisition signals Novartis’s confidence that Exl-111 can outperform this proven therapy by taking an entirely different approach.